ArticleDigestive diseases and sciences2025
Sonographic Transmural Induction Outcomes Across Advanced Therapies in Crohn's Disease.
Article in Digestive diseases and sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIntestinal ultrasound (IUS) is increasingly being used to evaluate induction efficacy in both clinical practice and clinical trials. We aimed to quantify the rates of induction IUS transmural (TM) remission and response across advanced therapies (AT) in Crohn's disease (CD).
methodsSingle-center retrospective review of patients with CD initiating AT with IUS pre- and post-induction. Primary outcome was induction TM segmental response (> 25% decrease in bowel wall thickness (BWT), absolute BWT decrease > 2 mm, or absolute BWT decrease > 1 mm with ≥ 1-point improvement in Modified Limberg Score (MLS) for bowel wall hyperemia of 0-3). Secondary outcomes were segmental and complete (all segments) TM remission (BWT ≤ 3.0 mm and MLS 0). Descriptive statistics summarized data (median [IQR]): univariate and multivariate tested associations.
results101 patients (53% female, age 17.4 years [15.0-21.1]); disease duration 0.80 years [0.17-3.96]. IUS performed 78 [56-102] days on AT (44% anti-TNF, 53% AT naïve). Segmental TM induction response and remission across all AT were 63% and 36%, respectively. Complete TM remission was 35% and was independently associated with infliximab (aOR 12.9 [2.1-79.8]), upadacitinib (aOR 10.4[1.4-75.4]), as well baseline MLS 3 (aOR 0.20[0.049-0.79]) and loss of bowel wall stratification on baseline IUS (aOR 0.21[0.056-0.77]).
conclusionsTransmural induction outcomes are achievable across multiple advanced therapies, with 2/3 of patients achieving a response and 1/3 of patients achieving complete remission. These data, combined with the high correlation between IUS and endoscopy, suggest that IUS response could be considered as a clinical trial endpoint.
Indexed as
Identifiers
40618289What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.